C-squared Pharma

Activities: Ingredients

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA...
  2. Buckland Group launches Quvara Medical after acquiring Becton Dickinson’s Swindon site to boost UK-EU medical manufacturing The acquisition establishes Quvara Medical as a new UK- and EU-based CMO offering GMP- and ISO-certified, high-volume manufacturing services to pharma and medtech clients
  3. Domino’s Adem Kulauzovic appointed to the Board of OMAC Domino’s Adem Kulauzovic appointed to the Board of OMAC to help shape the future of packaging automation
  4. Manufacturing Chemist Stand Side with Almac Group We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  5. Ardena strengthens leadership team with new quality and information officers Appointments reinforce focus on quality, compliance, and digital integration across global operations

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

Related Content

Manufacturing

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now